Poseida Therapeutics, Inc. | LinkedIn (original) (raw)

About us

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com.

Industry

Biotechnology Research

Company size

201-500 employees

Headquarters

San Diego, California

Type

Public Company

Founded

2014

Specialties

Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative Medicine, T-cells, Allogeneic, Oncology, Immuno-oncology, Immunology, Poseida, Cytotoxic T Lymphocytes, piggyBac®, piggyBac® DNA Modification System, Cas-CLOVER™, and TAL-CLOVER™

Locations

Employees at Poseida Therapeutics, Inc.

See all employees

Updates

Today we completed our merger with Roche, making Poseida a wholly owned subsidiary within Roche’s Pharmaceutical Division. Together we’ll continue to advance innovative therapies with the #capacitytocure. Learn more: https://lnkd.in/eDqaKhqM
Reflecting on the past year, we are grateful for the numerous achievements and milestones we've reached together. We wish all a happy and healthy New Year. Here's to a bright future ahead!
We’re thrilled to announce Poseida entered into a definitive agreement to be acquired by Roche Holdings, Inc. At the closing of the proposed transaction, Poseida and its employees will join the Roche Group and advance our innovative pipeline of non-viral, Tscm-rich CAR-T therapies and genetic medicines as part of Roche’s Pharmaceuticals Division. Details here: https://lnkd.in/gvbwFU7r #CapacitytoCure #celltherapy #CART #geneticmedicines
Poseida Therapeutics, Inc. reposted this

1,294 followers
2mo Edited
Join us at our November A2I Coffee Club on November 21 from 6:30pm-7:30pm on Zoom! This time we will focus on the Science and Scope of CAR T-cell Therapy with two specialists from Poseida Therapeutics! Register at https://lnkd.in/gnyfbSpU or by scanning QR code on flyer. Visit AWIS.org for membership details and email A2i@AWISSD.org for more meeting info.

Join now to see what you are missing

Join now

Poseida Therapeutics, Inc. | LinkedIn (original) (raw)

About us

Locations

Employees at Poseida Therapeutics, Inc.

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding